Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma

Kelly E. Craven, Jesse Gore, Murray Korc

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The importance of angiogenesis in pancreatic ductal adenocarcinoma (PDAC) and its therapeutic potential have been explored in both pre-clinical and clinical studies. Human PDACs overexpress a number of angiogenic factors and their cognate high-affinity receptors, and anti-angiogenic agents reduce tumor volume, metastasis, and microvessel density (MVD), and improve survival in subcutaneous and orthotopic pre-clinical models. Nonetheless, clinical trials using anti-angiogenic therapy have been overwhelmingly unsuccessful. This review will focus on these pre-clinical and clinical studies, the potential reasons for failure in the clinical setting, and ways these shortcomings could be addressed in future investigations of angiogenic mechanisms in PDAC.

Original languageEnglish (US)
JournalCancer Letters
DOIs
StateAccepted/In press - 2015

Fingerprint

Adenocarcinoma
Angiogenesis Inducing Agents
Microvessels
Tumor Burden
Clinical Trials
Neoplasm Metastasis
Survival
Therapeutics
Clinical Studies

Keywords

  • Angiogenesis
  • Pancreatic cancer
  • Vascular endothelial growth factor (VEGF)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. / Craven, Kelly E.; Gore, Jesse; Korc, Murray.

In: Cancer Letters, 2015.

Research output: Contribution to journalArticle

@article{343da3fb22c14eb1af2b8f5afae7211d,
title = "Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma",
abstract = "The importance of angiogenesis in pancreatic ductal adenocarcinoma (PDAC) and its therapeutic potential have been explored in both pre-clinical and clinical studies. Human PDACs overexpress a number of angiogenic factors and their cognate high-affinity receptors, and anti-angiogenic agents reduce tumor volume, metastasis, and microvessel density (MVD), and improve survival in subcutaneous and orthotopic pre-clinical models. Nonetheless, clinical trials using anti-angiogenic therapy have been overwhelmingly unsuccessful. This review will focus on these pre-clinical and clinical studies, the potential reasons for failure in the clinical setting, and ways these shortcomings could be addressed in future investigations of angiogenic mechanisms in PDAC.",
keywords = "Angiogenesis, Pancreatic cancer, Vascular endothelial growth factor (VEGF)",
author = "Craven, {Kelly E.} and Jesse Gore and Murray Korc",
year = "2015",
doi = "10.1016/j.canlet.2015.11.047",
language = "English (US)",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma

AU - Craven, Kelly E.

AU - Gore, Jesse

AU - Korc, Murray

PY - 2015

Y1 - 2015

N2 - The importance of angiogenesis in pancreatic ductal adenocarcinoma (PDAC) and its therapeutic potential have been explored in both pre-clinical and clinical studies. Human PDACs overexpress a number of angiogenic factors and their cognate high-affinity receptors, and anti-angiogenic agents reduce tumor volume, metastasis, and microvessel density (MVD), and improve survival in subcutaneous and orthotopic pre-clinical models. Nonetheless, clinical trials using anti-angiogenic therapy have been overwhelmingly unsuccessful. This review will focus on these pre-clinical and clinical studies, the potential reasons for failure in the clinical setting, and ways these shortcomings could be addressed in future investigations of angiogenic mechanisms in PDAC.

AB - The importance of angiogenesis in pancreatic ductal adenocarcinoma (PDAC) and its therapeutic potential have been explored in both pre-clinical and clinical studies. Human PDACs overexpress a number of angiogenic factors and their cognate high-affinity receptors, and anti-angiogenic agents reduce tumor volume, metastasis, and microvessel density (MVD), and improve survival in subcutaneous and orthotopic pre-clinical models. Nonetheless, clinical trials using anti-angiogenic therapy have been overwhelmingly unsuccessful. This review will focus on these pre-clinical and clinical studies, the potential reasons for failure in the clinical setting, and ways these shortcomings could be addressed in future investigations of angiogenic mechanisms in PDAC.

KW - Angiogenesis

KW - Pancreatic cancer

KW - Vascular endothelial growth factor (VEGF)

UR - http://www.scopus.com/inward/record.url?scp=84953439379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953439379&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2015.11.047

DO - 10.1016/j.canlet.2015.11.047

M3 - Article

C2 - 26723874

AN - SCOPUS:84953439379

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -